According to a study on non-steroidal anti-inflammatory drugs (NSAIDs), women with accompanying back pain who take naproxen, diclofenac, or etoricoxib — all of which are used to treat low-to-middle grade pain — are far less likely to ovulate after as short as ten days of consecutive use. Additionally, these women experience much lower levels of progesterone, with one third of patients suffering from functional cysts as a result. It is important to note that etoricoxib has not been approved by the FDA and diclofenac is offered only through prescription. Naxopren is the only NSAID available over the counter in the United States and found in Aleve, a popular painkiller. Researchers said the effect is only temporary, side effects are minor, and the drugs are otherwise safe, but clinicians are recommended to discuss these potential risks with female patients who have rheumatic diseases.
Read more at The Medical Daily’s The Grapevine.